|Home | About | Journals | Submit | Contact Us | Français|
Human papillomavirus (HPV) vaccines containing types 16 and 18 are remarkably effective in preventing cervical cancer associated with these HPV types. No information currently exists in Botswana concerning the HPV types causing precancerous or cancerous lesions.
The goal of this pilot project was to determine the HPV types causing precancerous cervical intraepithelial neoplasia (CIN) stages 2 and 3 in HIV-infected women in Gaborone, Botswana. HIV-infected women referred to our clinic with high-grade intraepithelial lesion (HSIL) on the Pap smear were enrolled in the study. Two specimens were obtained on all subjects, one for histopathology and the other for HPV typing. HPV typing was performed only if the histopathology results demonstrated CIN stage 2 or 3 disease. Histopathology results were corroborated at two sites: Lancet Laboratories (Johannesburg, South Africa) and University of Pennsylvania (Pennsylvania, United States). HPV typing was performed using linear array genotyping (CE-IVD, Roche Diagnostics).
This is an interim analysis of an intended sample size of 100 women. We identified 30 HIV-infected women with CIN stages 2 or 3 between August 11, 2009, and January 29, 2010. The median age was 36 (interquartile range [IQR], 33 - 38) and the median CD4 cell count was 427 cells/mm3 (IQR, 360-560 cells/mm3). Of the 30 women enrolled, 28 (93%) had co-infection by multiple HPV types. HPV type 52 was found in the 2 (7%) women carrying a single type. 15 (50%) had HPV types 16, 18, or both. 25 (83%) women, including all the ones not carrying the 16 or 18 types, carried other high-risk HPV types. Among the other high-risk types, HPV types 33, 35, and 58 were the most prevalent, accounting for 7 (23%), 8 (27%), and 10 (33%) cases, respectively.
HPV 16 and 18 are the most common types in HIV-infected women with CIN 2 or 3 in Gaborone, Botswana. However, other high-risk HPV types may account for a significant number of advanced CIN lesions in this population.
This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.